Riskpilot← Back to searchSign inGet full accessCamurus Oy
OYActiveY-tunnus 2864875-7Uudenmaankatu 15Manufacture of pharmaceutical preparations · NACE 2120Est. 20172 employees
Revenue 2024
EUR 685K
0% vs 2023
EBITDA margin
7.7%
-13% vs 2023
Equity ratio
0.0%
Financial strength
Net profit 2024
EUR 46K
-6% vs 2023
| Revenue | EUR 685K | +0% |
| EBITDA | EUR 53K | -13% |
| Net profit | EUR 46K | -6% |
| Total assets | EUR 555K | +16% |
| Equity | EUR 4 | +0% |
| Employees | 2 | — |
Legal name
Camurus Oy
Y-tunnus number
2864875-7
Legal form
Osakeyhtiö
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
25. lokakuuta 2017
Share capital
EUR 25 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja hallituksen jäsen yhdessä
Company purpose
Yhtiön toimiala on yhtiön, Camurus AB:n (NASDAQ Tukholma: CAMX) ja/tai muun, yhtiön kanssa samaan konserniin kuuluvan yhtiön omistamien ja/tai kehittämien lääketeollisuustuotteiden myynti ja markkinointi.
Address
Uudenmaankatu 15
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 681 | 763 | 663 | 685 | 685 |
| Staff expenses | −319 | −307 | −320 | −0 | −0 |
| EBITDA | 40 | 53 | 56 | 61 | 53 |
| Depreciation & amort. | — | — | — | −0 | −0 |
| EBIT | 40 | 53 | 56 | 61 | 53 |
| Net financials | −0 | −0 | −0 | 1 | 6 |
| Profit before tax | 39 | 53 | 56 | 62 | 59 |
| Tax | 8 | 11 | 8 | 14 | 13 |
| Net profit | 31 | 42 | 48 | 49 | 46 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 316 | 324 | 411 | 478 | 555 |
| Equity | 112 | 153 | 201 | 0 | 0 |
| Long-term debt | — | — | — | 0 | 0 |
| Short-term debt | 204 | 170 | 210 | 9 | 19 |
| Total debt | 204 | 170 | 210 | 228 | 260 |
EBITDA margin
7.7%
This company
15.8%
Market median
-51% vs market
20202024
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20202024
Return on equity
1140100.0%
This company
18.4%
Market median
+6196096% vs market
20202024
Net profit margin
6.7%
This company
8.1%
Market median
-17% vs market
20202024
Asset turnover
1.23×
This company
1.12×
Market median
+10% vs market
20202024
Debt / equity
138777.00×
This company
0.62×
Market median
-22383287% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
AM Audit | Audit | 2017 – 2020 |
KA | Audit | 2020 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2017 | |
| Chairperson | 2017 | |
| Former (2) | ||
| Board of Directors | 2017 – 2022 | |
| Board of Directors | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Camurus Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anne Maria Lindgren | Audit | 0 companies |
| Karsten Anders Westerling | Audit | 0 companies |
| Eva Maria Pinotti-Lindqvist | Board of Directors | 0 companies |
| Anders Vadsholt | Board of Directors | 0 companies |
| Jon Uguzne Garay Alonso | Board of Directors | 0 companies |
| Richard Major Jameson | Board of Directors | 0 companies |
| Sven Fredrik Tiberg | Chairperson | 0 companies |